Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

benzinga.com/markets/earnings/25/10/48569116/gileads-hiv-drugs-power-earnings-beat-company-eyes-multiple-launches-by-2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.
GILD is in positive territory. Get the complete picture here
The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45…

This story appeared on benzinga.com, 2025-10-31 17:41:12.
The Entire Business World on a Single Page. Free to Use →